Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Dominant-negative HNF1α mutant promotes liver steatosis and inflammation by regulating hepatic complement factor D

ABSTRACT: Heterozygous mutations of HNF1A gene are the pathogenic cause of MODY3. A few studies reported that MODY3 patients may have dyslipidemia and early onset of liver steatosis in some cases. However, there is a lack of sufficient and reliable experimental evidence on how HNF1α regulates NAFLD progression under the genetic background of MODY3. We established a novel mouse model carrying the dominant-negative human HNF1α P291fsinsC mutation (termed as hHNF1Amut/- mice). The hepatic morphological phenotypes and the changes of lipid metabolism were investigated. To reveal the molecular changes, we performed the transcriptome and proteome analysis.

ORGANISM(S): Mus musculus

PROVIDER: GSE224953 | GEO | 2023/08/09

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Dominant-negative HNF1α mutant promotes liver steatosis and inflammation by regulating hepatic complement factor D

Project description:Dominant-negative HNF1α mutant promotes liver steatosis and inflammation by regulating hepatic complement factor D

| PRJNA933171 | ENA

Human HNF1A KI mice liver proteome analysis

Project description:Nonalcoholic fatty liver disease (NAFLD) is a pathological condition caused by excessive fat accumulation in liver. HNF1A is the pathogenic cause of hepatocellular adenoma and HCC. It is an important transcription factor in liver. We constructed a knock-in mice expressing a human dominant negative HNF1α P291fsinsC mutation to explore how the pathogenic mutant affected lipid metabolism. Three liver samples of control group and four liver samples of KI group were used to do proteome analysis.

2023-03-02 | PXD040561 |

Decreased GLUT2 expression and defective glucose uptake in MODY3 human iPSC-Derived beta cells

Project description:Purpose: To investigate the impact of HNF1A mutation on the development of pancreatic endocrine progenitors using differentiated control and MODY3-hiPSCs Methods: ChIP-Seq was performed on pancreatic endocrine progenitors obtained on day 20 of the directed differentiation of control hPSCs (1 clone from H9 and 3 clones from iAgB-hiPSC) and hiPSCs from MODY3 patients (3 clones from P2. Peak calling analyses were carried out. qRT-PCR validation was also performed using SYBR Green assays. Results: ChIP-Seq analysis revealed that numerous HNF1A target genes were downregulated in MODY3-hiPSC-derived pancreatic endocrine progenitors. Altered expression of a number of genes were further confirmed with qRT-PCR. Conclusions: The H126D mutation in HNF1A does not affect the expression levels of HNF1A. However, this mutation affects the DNA binding capability of the transcription factor, thereby resulting in deficiency in the gene expression of proteins that are essential to maintain normal human beta-cell function for insulin secretion.

2021-03-22 | GSE139832 | GEO

Lysine 117 Residue is Essential for the Function of the Hepatocyte nuclear factor 1α

Project description:Hepatocyte nuclear factor 1α (HNF1α) play essential roles in controlling development and metabolism, its mutations are clearly linked to the occurrence of maturity-onset diabetes of the young (MODY3) in human. 117 lysine to glutamic acid (E117) mutation in the HNF1α gene was clinically associated with MOYD3, but no functional data on this variant is available. Here, we generated a knock-in mouse model in which the lysine 117 is replaced with glutamic acid in the endogenous murine HNF1α locus. The HNF1αE117/E117 mice reproduced HNF1-null phenotypes including dwarfism, hepatic dysfunction, renal Fanconi syndrome, diabetes and die from a progressive wasting syndrome, but no hyperphenylalaninemia. Moreover, HNF1αE117/E117 mice shared similar hepatic gene expression profiles with HNF1 deficient mice. In vitro experiments showed that HNF1 mutants in which the lysine 117 residue were replaced by glutamic acid, arginine or glutamine residues, respectively, had a significant decreased in overall transactivation and DNA binding capacity. K117 mutants had no effect on its protein stabilities and nuclear localization, but significantly blocked its own association. Our results clearly demonstrate that the lysine 117 residue is essential for the function of the HNF1a, and prove important to identify the molecular basis for diseases associated with defects in HNF1α We then performed gene expression profiling analysis using data obtained from RNA-seq of liver tissue of 3 WT mice and 3 KI mice.

2023-01-01 | GSE207758 | GEO

Effect of HNF1A-MODY on stem cell islets [S4 bulk rna seq]

Project description:This project investigates the impact of the hotspot mutation P291fsinsC in HNF1A-MODY (Maturity-Onset Diabetes of the Young) on stem cell-derived islets. RNA sequencing (RNA-seq) was performed on islets differentiated from mutant and control HNF1A-MODY stem cells to study the mutation's effect on gene expression. By comparing the transcriptomic profiles of these islets, the study aims to uncover molecular mechanisms underlying the dysfunction caused by the P291fsinsC mutation during islet development and maturation.

2026-02-11 | GSE291570 | GEO

Effect of HNF1A-MODY on stem cell islets [II]

2026-02-11 | GSE288932 | GEO

Effect of HNF1A-MODY on stem cell islets [scRNA-Seq]

2026-03-30 | GSE300388 | GEO

Effect of HNF1A-MODY on stem cell islets [scRNA-seq]

2026-03-30 | GSE288431 | GEO

Effect of HNF1A-MODY on stem cell islets

2026-03-30 | GSE284213 | GEO

Hepatocyte Deletion of Triglyceride-Synthesis Enzyme DGAT2 Reduces Steatosis without Increasing Inflammation or Fibrosis

Project description:Non-alcoholic fatty liver disease (NAFLD) is characterized by excess lipid accumulation in hepatocytes and reprepresents a huge public health problem owing to its propensity to progress to non-alcoholic steatohepatitis (NASH), fibrosis, and liver failure. The lipids stored in hepatic steatosis are primarily triglycerides (TGs) synthesized by two acyl CoA:diacylglycerol acyltransferase (DGAT) enzymes. Either DGAT1 or DGAT2 catalyzes this reaction, and these enzymes have been suggested to differentially utilize exogenous or endogenously synthesized fatty acids, with DGAT2 being linked to storage of fatty acids from de novo lipogenesis, a process that is increased in NAFLD. However, whether DGAT2 is more responsible for lipid accumulation in NAFLD and the progression to fibrosis is currently unknown. Also, it is unresolved whether DGAT2 can be safely inhibited as a therapy for NAFLD. Here we induced NAFLD-like disease in mice by feeding a diet rich in fructose, saturated fat, and cholesterol and found that hepatocyte-specfici Dgat2 deficiency reduced expression of de novo lipogenesis genes and lowered liver TGs by ~70%. Importantly, the reduction of steatosis was not accompanied by increased inflammation or fibrosis, and insulin and glucose metabolism were unchanged. Conclusion: This study suggests that hepatic DGAT2 deficiency successfully reduced diet-induced hepatic steatosis and supports the development of DGAT2 inhibitors as a therapeutic strategy for treating NAFLD and preventing downstream consequences.

2020-05-26 | PXD013423 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data